Swixx BioPharma

Swixx BioPharma (Swixx) is the largest independent pharmaceutical commercialisation platform across rest-of-world markets, spanning over 45 countries throughout Central and Eastern Europe, several CIS markets, Latin America, parts of the Middle East, and Turkey.

Founded in 2014, Swixx serves as a ready-made commercial partner for pharmaceutical companies seeking to sell branded prescription drugs in markets where they lack a local presence, managing market access, regulatory approvals, logistics, compliance, sales forces and medical networks on their behalf. The business commercialises drugs for nearly 80 partners, including large multinational companies like Sanofi, Lundbeck and Bristol Myers Squibb but also biotechs such as BridgeBio, Incyte, Krystal Biotech and Madrigal.

• Large and growing market: Swixx operates in a large, underpenetrated addressable market across its core regions (EUR45 to EUR50bn). Only ~20% of drug spend is currently outsourced to partners like Swixx, a share expected to rise to ~30% by 2029, with the outsourced segment growing 10 to 12% a year.
• Differentiated platform: Pharmaceutical companies prefer to work with a single partner covering many countries rather than managing numerous small regional vendors. Swixx’s presence across over 45 countries, combined with its comprehensive local coverage, broad range of therapeutic areas and professional workforce coming from international pharma, makes it an increasingly attractive choice.
• Clear value creation agenda: SK Capital Partners has a well-defined plan to build on Swixx’s strong momentum and drive its next phase of growth.
• Sponsor fit: With a ~20-year track record across the pharmaceutical value chain and deep sector expertise, SK Capital Partners brings a proven playbook for scaling businesses like Swixx.

Resilient, non-cyclical demand: Spending on branded prescription medicines is largely inelastic and has historically proven resilient through economic cycles, underpinning a durable revenue base. At the same time, pharmaceutical companies’ structural shift toward outsourcing in complex, smaller markets provides a long runway for continued growth.

Network effects and single-partner advantage: With each new partner and market it adds, Swixx increases its density and value proposition, reinforcing its appeal to prospective partners while creating opportunities to expand relationships with existing clients.

Sticky, long-term contracts: Swixx’s partnerships are typically multi-year and highly durable, resulting in strong retention across its partner base. These deep, long-standing relationships give Swixx early insight into partners’ pipelines and a natural inside track on new product launches, positioning the business to capture growth as partners bring new medicines to market.

Operational improvement upside: Reinvigorating business development function with additional resources, opportunity to upgrade operational processes, and pursuing selective acquisitions to enter new geographies represent clear, actionable levers.

SK Capital Partners is a New York-based middle-market buyout firm focused on the material sciences, specialty ingredients, and life sciences sectors. Pantheon has  a primary relationship with SK Capital Partners and has co-invested alongside the firm previously, and this relationship provided the basis for securing allocation in Swixx.